- FDA approves Checkpoint Therapeutics' drug Unloxcyt for cutaneous squamous cell carcinoma treatment.
- Unloxcyt is a PD-L1 antibody that enhances the immune system to combat cancer cells.
- Positive overall response rate in clinical study of 109 patients.
- Approval covers locally advanced and metastatic forms of the disease.
- Unloxcyt showed an overall response rate of 47% in patients with metastatic cancer and 48% in those with an advanced local form of the disease.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
